You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞製藥-B(09966.HK):KN046聯合KN026治療局部晚期不可切除或轉移性HER2陽性實體癌II期臨牀試驗初步結果已獲准於2022年AACR年會以電子海報形式展示
格隆匯 03-09 07:43

格隆匯3月9日丨康寧傑瑞製藥-B(09966.HK)發佈公吿,KN046(一種重組人源化PD-L1/CTLA-4雙特異性抗體)聯合KN026(一種HER2靶向雙特異性抗體)用於治療局部晚期不可切除或轉移性HER2陽性實體癌患者的初步安全性及療效的II期臨牀試驗結果摘要已獲准並計劃於即將舉行的2022年AACR年會以電子海報形式展示。摘要及電子海報(摘要編號:CT542)將於2022年4月8日(星期五)下午一時正(美國東岸時間(US ET))公佈,也將於公司網站 http://www.alphamabonc.com相應公佈。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account